By
Marcello Ferrada de Noli, Swedish professor emeritus of public health sciences esp. epidemiology, former Research Fellow at Harvard Medical School. At a time when utmost altruism is crucial in vaccinating the Covid-19-ridden world, the ‘best vaccine’ award went to a jab made by a greedy corporation that seems more interested in protecting its profits than spreading the shot.
Fresh reports on the real mortality toll taken by the Covid-19 pandemic and a galloping upsurge of new infections in widely populated regions call on all governments to urgently institute this one and only priority: to drastically expand and increase vaccination programs worldwide, using
OREANDA-NEWS. The decision of the World Vaccine Congress to give the palm to the American drug for the coronavirus Moderna was geopolitically motivated, the Russian Sputnik V is not worse than the American vaccine, says Mark van Ranst, one of the leading virologists and the most cited experts in Belgium in the field of COVID-19.
The development of the American company Moderna and the US National Institutes of Health was recognized as the best vaccine for COVID-19 at the online World Vaccine Congress Washington 2021 on Wednesday. Moderna s drug, licensed for emergency use in the United States and several other countries, has surpassed AstraZeneca, Bharat Biotech, Janssen, Medicago, Novavax, Pfizer / BioNtech, Sputnik V, and Zoetis, an animal drug.
5/4/2021 10:53:27 AM GMT | By Stocks Reporter
NASDAQ:VXRT plummets by 25.60% on Monday amidst another rocky day for the NASDAQ.
Vaxart Inc misses revenue estimates during its earnings call before the markets opened.
Vaxart is preparing to give a presentation for its oral COVID-19 vaccine candidate on Tuesday.
NASDAQ:VXRT has had an awful start to 2021 and after briefly hitting highs of $24.90, the stock has fallen nearly 70% despite having a potentially groundbreaking vaccine coming down the pipe. On Monday, Vaxart shareholders woke up to a surprise as the quarterly earnings call did not quite go as planned.
Shares plummeted by 25.60% during trading hours, to close the day at $8.02, although much of that has been regained during after hours trading. Vaxart is still trading above both its 50-day and 200-day moving averages, and has still comfortably outpaced the S&P 500 index over the past 52-weeks.
Original:
Vaxart (
VXRT) - Get Report shares fell Monday, reversing gains in premarket trading, ahead of a presentation from the company’s founder and chief scientific officer that is expected to reveal its Phase 1 clinical trials of an oral vaccine that shows promise in protecting against COVID variants.
Shares of Vaxart were up 12.62% at $12.14 in premarket trading ahead of the presentation from its founder and chief scientific officer, Dr. Sean Tucker, on the importance of T-cell immunity in COVID-19 vaccines.
At the open, the stock fell 7.51% to $9.97. The oral vaccine development firm’s name has popped up frequently in social media chat rooms.